Wadden et al. Nutrition Metabolism 2013, ten:33 http://nutritionandmetabolism/content/10/1/Page eight of4.5.six.seven.eight. 9.ten.11.12.13.14.15.sixteen.17. 18. 19.twenty.21.22.23.24.25.Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, Holst JJ: Incretin secretion in relation to meal dimension and body bodyweight in healthful subjects and people today with form 1 and style 2 diabetes mellitus. J Clin Endocrinol Metab 2003, 88:2706?713. Deacon CF, Johnsen AH, Holst JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that may be a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995, 80:952?57. Hansen L, Deacon CF, Orskov C, Holst JJ: Glucagon-like peptide-1-(7?6) amide is transformed to glucagon-like peptide-1-(9?six)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of your porcine intestine. Endocrinology 1999, 140:5356?363. Meier JJ, Deacon CF, Schmidt WE, Holst JJ, Nauck MA: Suppression of glucagon secretion is reduced immediately after oral glucose administration than through intravenous glucose administration in human subjects. Diabetologia 2007, 50:806?13. Kazakos KA, Sarafidis PA, Yovos JG: The impact of diabetic autonomic neuropathy around the incretin effect. Med Sci Monit 2008, 14:CR213 R220.3-Formyl-1H-indazole-5-carboxylic acid Purity Orskov C, Holst JJ, Nielsen OV: Impact of truncated glucagon-like peptide-1 [proglucagon-(78?07) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988, 123:2009?013. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA: Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7?six) amide in kind I diabetic sufferers.Price of 2-Iodo-4-methoxybenzonitrile Diabetes Care 1996, 19:580?86. de Heer J, Rasmussen C, Coy DH, Holst JJ: Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype two) during the perfused rat pancreas. Diabetologia 2008, 51:2263?270. Larsen PJ, Vrang N, Tang-Christensen M: Central pre-proglucagon derived peptides: options for therapy of obesity. Curr Pharm Des 2003, 9:1373?382. Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rossner S, Hellstrom PM: Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese guys. Int J Obes Relat Metab Disord 1999, 23:304?11. Flint A, Raben A, Astrup A, Holst JJ: Glucagon-like peptide one promotes satiety and suppresses power intake in people. J Clin Invest 1998, 101:515?twenty. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH: Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic results in nutritious people.PMID:33395538 Am J Physiol 1997, 273:E981 988. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in guy. Dig Dis Sci 1993, 38:665?73. Nauck M, Stockmann F, Ebert R, Creutzfeldt W: Lowered incretin impact in style two (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46?two. Holst JJ: Treatment of variety two diabetes mellitus determined by the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002, 18:430?41. Holz GG, Chepurny OG: Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use from the remedy of diabetes mellitus. Curr Med Chem 2003, 10:2471?483. Holst JJ, Schwartz TW, Lovgreen NA, Pedersen O, Beck-Nielsen H: Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon.